Johnson & Johnson halts late-stage E.coli vaccine trial
Pharmaceutical giant Johnson & Johnson (JNJ) is planning to sell its stroke care business called “Cerenovus” for $1 billion ...
Johnson & Johnson (NYSE:JNJ), the New Jersey-based healthcare company, is planning to sell its stroke care business, ...
The Motley Fool on MSN13d
Did Johnson & Johnson Just Give Investors 23 Billion Reasons to Buy Its Stock?To give some idea of the sheer size of Johnson & Johnson, a glance at its reported sales figure is revealing. In the fourth ...
Johnson & Johnson has put its stroke care business up for sale, aiming for a valuation of more than $1bn, as part of its ...
HOUSE, Pa. - Johnson & Johnson (NYSE: NYSE:JNJ) has released new data on nipocalimab, an investigational drug with potential to treat diseases driven by immunoglobulin G (IgG) antibodies. Published in ...
The healthcare leader is also an excellent income stock. Johnson & Johnson has increased its dividend payout for 62 ...
Duato discusses the split of the business, dealing with the scrutiny brought about by lawsuits, and 2025 priorities.
Johnson & Johnson is considering selling its stroke care unit, Cerenovus, in a potential $1 billion deal as part of its ...
Johnson & Johnson introduces TECNIS PureSee IOL for presbyopia in India, offering high-quality vision and reduced visual ...
A class action filed today says Kiwis have been deceived for about two decades through the use of phenylephrine in cold and ...
Joseph J. Wolk, Executive Vice President and Chief Financial Officer of Johnson & Johnson (NYSE:JNJ), recently sold shares of the company's stock. According to a recent SEC filing, Wolk sold 13,015 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback